Noopept
Also called Omberacetam, GVS-111
Oral (by mouth)Human study reference
Research reference
Human study
Noopept–piracetam comparative study
20 mg per day divided into two doses
56 days
Neznamov and Teleshova, Neuroscience and Behavioral Physiology (2009) ↗When results may show
- When change was measured
- Cognitive symptoms were assessed during an active-comparator study, not a robust placebo-controlled healthy-person enhancement trial.
- When to assess
- 56 days
- Conditions and limitations
- Adults with vascular or post-traumatic cognitive impairment. This oral study does not validate nasal dosing, a universal cognitive starter, long-term cycling or durable benefit after stopping.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 2hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Neznamov and Teleshova, Neuroscience and Behavioral Physiology (2009)This oral study does not validate nasal dosing, a universal cognitive starter, long-term cycling or durable benefit after stopping.